{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-209259","form_type":"8-K","ticker":"JANX","cik":"0001817713","company_name":"Janux Therapeutics, Inc.","filed_at":"2025-09-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.103354+00:00","generated_at":"2026-05-17T06:08:07.626672+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Janux Therapeutics CSO Byron Robinson departs effective Sept 18, 2025","bullets":["Byron Robinson, Ph.D., Chief Strategy Officer, departed Janux effective September 18, 2025.","Company determined termination without 'Cause' under Change in Control and Severance Benefit Plan.","No successor or interim CSO announced; departure of named executive officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-209259","json":"https://secwatch.observer/filing/0001193125-25-209259.json","markdown":"https://secwatch.observer/filing/0001193125-25-209259.md","text":"https://secwatch.observer/filing/0001193125-25-209259.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817713/000119312525209259/0001193125-25-209259-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817713/000119312525209259/janx-20250918.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:08:07.626672+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}